ArticleFrontiers in pharmacology2026
The role of ginkgo leaf extract and dipyridamole adjuvant treatment for reduction of lower limb deep vein thrombosis after proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fracture.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Postoperative lower limb deep vein thrombosis (DVT) remains a critical complication following proximal femoral nail antirotation (PFNA) surgery for intertrochanteric femoral fracture (IFF) in the elderly. This study aimed to assess the efficacy of adjuvant Ginkgo Leaf Extract and Dipyridamole (GLED) therapy in reducing DVT incidence. Methods: This retrospective cohort study included elderly patients with intertrochanteric fractures treated with PFNA between August 2018 and July 2022. Patients were divided into a conventional group receiving rivaroxaban and a GLED group receiving rivaroxaban plus GLED. Evaluations included DVT incidence (postoperative days 0-7, 8-14, 15-21) and measurements of coagulation parameters, hemorheological parameters, and inflammatory markers at 8 h and 7 days post-surgery. Results: The analysis involved 227 patients (126 conventional, 101 GLED). The DVT incidence in the GLED group was significantly lower at 8-14 days (4.08% vs. 12.71%; p = 0.047) and 15-21 days (1.06% vs. 11.65%; p = 0.007). At 7 days, the GLED group showed significantly prolonged activated partial thromboplastin time (31.75 s vs. 31.24 s; p = 0.020) and prothrombin time (13.75 s vs. 13.52 s; p = 0.012), lower fibrinogen (3.18 g/L vs. 3.85 g/L; p < 0.001) and D-dimer (225.41 μg/L vs. 338.74 μg/L; p < 0.001), reduced blood viscosity (low shear: 13.14 vs. 15.26 mPa·s; p < 0.001), and decreased inflammatory markers (Interleukin-8: 21.29 vs. 22.62 pg/mL; p = 0.002). Conclusion: Adjuvant GLED therapy is associated with a significantly lower subacute DVT incidence after PFNA in this retrospective cohort. Further prospective studies are required to confirm a causal relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.